Clinical Trial 50341

Marlton, NJ 08053


A Phase 1, Open-label, Multicohort Study to Evaluate the Impact of Inhibitors and Inducers of Cytochrome P450 Enzyme (CYP)3A and/or P-glycoprotein (P-gp) on the Pharmacokinetics (PK) of Vesatolimod (VES) in Virologically Suppressed Adults With HIV-1 on Antiretroviral Therapy (ART).

Qualified Participants Must:

• Be atleast 18 years old
• Be diagnosed with HIV-1
• Be currently on an ART regimen for at least 6 consecutive months, with no change in the ART regimen within 2 months prior to screening
• Refrain from the use of nicotine or nicotine-containing products 90 days prior to first dose of study drug and during the course of the study through the follow-up visit

Qualified Participants May Receive:

  • Up to $4,000
  • Tranportation available and no insurance needed

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.